AstraZeneca PLC (NASDAQ:AZN) Shares Bought by D.B. Root & Company LLC

D.B. Root & Company LLC grew its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 4.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 8,919 shares of the company’s stock after acquiring an additional 345 shares during the period. D.B. Root & Company LLC’s holdings in AstraZeneca were worth $695,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Stratos Wealth Advisors LLC lifted its holdings in shares of AstraZeneca by 2.0% in the third quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock valued at $522,000 after purchasing an additional 133 shares in the last quarter. Bruce G. Allen Investments LLC lifted its holdings in shares of AstraZeneca by 19.1% in the second quarter. Bruce G. Allen Investments LLC now owns 860 shares of the company’s stock valued at $67,000 after purchasing an additional 138 shares in the last quarter. Carnegie Investment Counsel lifted its holdings in shares of AstraZeneca by 0.8% in the second quarter. Carnegie Investment Counsel now owns 17,269 shares of the company’s stock valued at $1,347,000 after purchasing an additional 138 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in shares of AstraZeneca by 40.6% in the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after purchasing an additional 146 shares in the last quarter. Finally, Sunpointe LLC lifted its holdings in shares of AstraZeneca by 4.5% in the second quarter. Sunpointe LLC now owns 3,419 shares of the company’s stock valued at $267,000 after purchasing an additional 147 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Price Performance

NASDAQ AZN opened at $63.85 on Thursday. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The stock’s 50-day moving average is $78.45 and its two-hundred day moving average is $78.75. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. The firm has a market cap of $197.97 billion, a P/E ratio of 30.85, a price-to-earnings-growth ratio of 1.32 and a beta of 0.47.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday. Finally, TD Cowen upped their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, AstraZeneca presently has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.